GLP-1 Receptor Agonists and Sleep Quality in Patients with Type 2 Diabetes. Retrieved November 30, 2025
doi: 10.1155/2021/3687700 4 YokoyamaYKubo-KanedaMSunadaKTeishikataYKitamuraAOkamotoKet al
Yes, some individuals may experience nausea, bloating, or stomach discomfort while taking this medicine
The Companys lead candidate, pemvidutide, is a unique dual-action therapy targeting both glucagon and GLP-1 receptors in a balanced 1:1 ratio in development for the treatment of metabolic dysfunction-associated steatohepatitis (MASH), alcohol use disorder (AUD) and alcohol-associated liver disease (ALD)
Murine-based studies have shown that DPP-4 inhibition directly results in increased GLP-1 secretion and improves both overall insulin section and glucose tolerance
"Incretin-based glucose-lowering medications and the risk of acute pancreatitis and malignancies: a meta-analysis based on cardiovascular outcomes trials"